Literature DB >> 9678486

Thromboxanes: synthase and receptors.

R F Shen1, H H Tai.   

Abstract

Thromboxane A2 is a biologically potent arachidonate metabolite through the cyclooxygenase pathway. It induces platelet aggregation and smooth muscle contraction and may promote mitogenesis and apoptosis of other cells. Its roles in physiological and pathological conditions have been widely documented. The enzyme that catalyzes its synthesis, thromboxane A2 synthase, and the receptors that mediate its actions, thromboxane A2 receptors, are the two key components critical for the functioning of this potent autacoid. Recent molecular biological studies have revealed the structure-function relationship and gene organizations of these proteins as well as genetic and epigenetic factors modulating their gene expression. Future investigation should shed light on detailed molecular signaling events specifying thromboxane A2 actions, and the genetic underpinning of the enzyme and the receptors in health and disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9678486     DOI: 10.1007/bf02253465

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  20 in total

1.  Protein kinase C isoform ε negatively regulates ADP-induced calcium mobilization and thromboxane generation in platelets.

Authors:  Yamini S Bynagari-Settipalli; Parth Lakhani; Jianguo Jin; Kamala Bhavaraju; Mario C Rico; Soochong Kim; Donna Woulfe; Satya P Kunapuli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-02-23       Impact factor: 8.311

2.  Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion.

Authors:  Anders Gabrielsen; Hong Qiu; Magnus Bäck; Mats Hamberg; Anne-Louise Hemdahl; Hanna Agardh; Lasse Folkersen; Jesper Swedenborg; Ulf Hedin; Gabrielle Paulsson-Berne; Jesper Z Haeggström; Göran K Hansson
Journal:  J Mol Med (Berl)       Date:  2010-04-12       Impact factor: 4.599

Review 3.  Prostacyclin receptor regulation--from transcription to trafficking.

Authors:  C Midgett; J Stitham; K A Martin; J Hwa
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

Review 4.  The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.

Authors:  Prasanna Ekambaram; Wanyu Lambiv; Rosanna Cazzolli; Anthony W Ashton; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins.

Authors:  L Walch; V de Montpreville; C Brink; X Norel
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Altered coronary microvascular serotonin receptor expression after coronary artery bypass grafting with cardiopulmonary bypass.

Authors:  Michael P Robich; Eugenio G Araujo; Jun Feng; Robert M Osipov; Richard T Clements; Cesario Bianchi; Frank W Sellke
Journal:  J Thorac Cardiovasc Surg       Date:  2009-07-25       Impact factor: 5.209

7.  Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist.

Authors:  William S Wright; Jodine E Messina; Norman R Harris
Journal:  Exp Eye Res       Date:  2008-11-01       Impact factor: 3.467

8.  Integrative meta-analysis of differential gene expression in acute myeloid leukemia.

Authors:  Brady G Miller; John A Stamatoyannopoulos
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

9.  Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5-sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets.

Authors:  Kamala Bhavaraju; Soochong Kim; James L Daniel; Satya P Kunapuli
Journal:  Eur J Pharmacol       Date:  2007-11-17       Impact factor: 4.432

10.  Molecular evolution and functional divergence of the cytochrome P450 3 (CYP3) Family in Actinopterygii (ray-finned fish).

Authors:  Jun Yan; Zhonghua Cai
Journal:  PLoS One       Date:  2010-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.